You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 12,029,779

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,029,779

Title:	Semaglutide in medical therapy
Abstract:	The present invention relates to semaglutide for use in weight management.
Inventor(s):	Marianne Oelholm Larsen Groenning, Lars Endahl, Charlotte Giwercman Carson, Anders Bjerring Strathe, Maria Kabisch, Thomas Hansen
Assignee:	Novo Nordisk AS
Application Number:	US16/844,552
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,029,779
Patent Claims:	1. A method for reducing body weight of a subject in need thereof, comprising administering semaglutide subcutaneously to the subject in an amount of about 2.4 mg weekly. 2. The method according to claim 1, wherein the semaglutide is administered once weekly. 3. The method according to claim 1, wherein the subject is overweight. 4. The method according to claim 1, wherein the subject suffers from obesity. 5. The method according to claim 1, wherein the subject has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, dyslipidemia, sleep apnoea, and urine incontinence. 6. The method according to claim 5, wherein the subject has type 2 diabetes mellitus. 7. A method for reducing body weight of a subject in need thereof, comprising administering semaglutide subcutaneously to the subject in an amount of 2.4 mg once weekly. 8. The method according to claim 7, wherein the subject is overweight. 9. The method according to claim 8, wherein the subject has type 2 diabetes mellitus. 10. The method according to claim 7, wherein the subject is suffering from obesity. 11. The method according to claim 10, wherein the subject has type 2 diabetes mellitus. 12. The method according to claim 7, wherein the subject has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, dyslipidemia, sleep apnea, and urine incontinence. 13. The method according to claim 1, wherein the subject is overweight and has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, and dyslipidemia. 14. The method according to claim 7, wherein the subject is overweight and has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, and dyslipidemia.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.